entinostat has been researched along with Cutaneous T-Cell Lymphoma in 2 studies
Excerpt | Relevance | Reference |
---|---|---|
" The extreme photopotency of UVASens allows the use of lower radiation doses minimising the carcinogenic risks associated with the long-term use of phototherapy." | 1.40 | Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells. ( Karagiannis, TC; Sung, JJ; Ververis, K, 2014) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sung, JJ | 1 |
Ververis, K | 1 |
Karagiannis, TC | 1 |
Kato, Y | 1 |
Egusa, C | 1 |
Maeda, T | 1 |
Tsuboi, R | 1 |
2 other studies available for entinostat and Cutaneous T-Cell Lymphoma
Article | Year |
---|---|
Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells.
Topics: Benzamides; Cell Death; Cell Survival; DNA Damage; DNA Repair; Histone Deacetylase Inhibitors; Human | 2014 |
Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Topics: Acetylation; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzoat | 2016 |